Prednisolone acetate
- Generic Name
- Prednisolone acetate
- Brand Names
- Blephamide, Econopred Plus, Flo-pred, Pred Forte, Pred Mild, Pred-G
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30O6
- CAS Number
- 52-21-1
- Unique Ingredient Identifier
- 8B2807733D
- Background
Prednisolone acetate is a prednisolone molecule bound to an acetate functional group by an ester bond.
Prednisolone acetate was granted FDA approval in 1955.
- Indication
Prednisolone acetate is indicated as an anti-inflammatory or immunosuppressive agent for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, or infectious conditions. Prednisolone acetate is also indicated in organ transplant patients, as well as endocrine or neoplastic conditions.
- Associated Conditions
- Inflammation, Inflammatory Conditions, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Transplanted Organ Rejection
VivaVision's VVN461 Shows Promising Results in Phase 2 Trial for Non-Infectious Anterior Uveitis
• VivaVision Biotech's dual JAK1/TYK2 inhibitor VVN461 demonstrated non-inferior efficacy to prednisolone acetate in treating non-infectious anterior uveitis in a Phase 2 trial conducted across 10 clinical sites in China.
• Both 0.5% and 1.0% concentrations of VVN461 showed statistically significant improvements in anterior chamber cell grade with no substantial treatment-related adverse events, suggesting a potentially safer alternative to corticosteroids.
• The company plans to discuss Phase 3 clinical trials with Chinese regulatory authorities and request a type C meeting with the FDA, potentially advancing a new non-steroidal treatment option for the estimated 3 million uveitis patients in China.
Real-World Analysis of Nirmatrelvir/Ritonavir Drug-Drug Interactions Shows Low Reporting Rate
• A recent analysis of Pfizer's global safety database reveals a low reporting rate (0.005%) of drug-drug interactions (DDIs) associated with nirmatrelvir/ritonavir (NMV/r).
• Simvastatin was the most frequently reported contraindicated drug, while tacrolimus was the most common drug used with caution in NMV/r-related DDI cases.
• The majority (66.8%) of reported DDI cases were nonserious, with common adverse events including altered taste and gastrointestinal issues, aligning with NMV/r's known safety profile.
• The study underscores the importance of careful patient selection and medication management to mitigate DDI risks, supporting the safe use of NMV/r in treating COVID-19.
Dazdotuftide Eye Drops Show Promise in Non-Infectious Uveitis Treatment
• Dazdotuftide (TRS01) eye drops demonstrate a favorable safety profile, suggesting potential as a first-line treatment for non-infectious anterior uveitis.
• In a Phase 3 trial, TRS01 showed non-inferiority to prednisolone in reducing ocular pain and anterior chamber flare, with fewer IOP elevation risks.
• A subset of uveitic glaucoma patients treated with TRS01 experienced resolution of inflammation and stable intraocular pressure, indicating potential benefits.
• TRS01's unique mechanism of action targets ocular blinding diseases, offering a steroid-free alternative to manage inflammation without steroid-related side effects.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath